Vertex Pharmaceuticals Incorporated (VRTX)Healthcare | Biotechnology | Boston, United States | NasdaqGS
507.00 USD
-3.08
(-0.604%) ⇩
(Oct. 12, 2026, 4 p.m.
EDT)
|
Hot Take ↕ | Oct. 10, 2026, 8:09 a.m. EDT
Vertex Pharmaceuticals represents a rare combination of exceptional business quality and a temporary technical dislocation. The underlying franchise is unambiguously excellent, boasting a 23.5% return on equity, robust 12.5% revenue growth, and a fortress balance sheet with net cash on hand. Over the past nine years, the stock has delivered a 374% cumulative return, proving the market's enduring confidence in the management team and pipeline, despite a single year of price weakness recently. While the stock trades below its 50-day moving average, the 200-day average provides a sturdy foundation, and options flow suggests institutional players see significant upside potential ahead. There is no dividend yield to rely on, so investors must accept total capital appreciation as the sole return driver. For a patient buyer, the recent pullback offers a compelling entry point into a dominant healthcare compounder. |
| Model | MAE |
|---|---|
| AutoTheta ✓ | 0.036755 |
| MSTL | 0.061833 |
| AutoARIMA | 0.062918 |
| AutoETS | 0.062919 |
Forecast horizon: 45 days | Selected: AutoTheta
| Forecast Reliability | |
|---|---|
| Score | 48% |
| H-stat | 1.97 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.105 |
| Excess Kurtosis | -1.45 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 9.767 |
| Revenue per Share | 49.507 |
| Market Cap | 128,423,100,416 |
| Trailing P/E | 29.53 |
| Forward P/E | 25.22 |
| Beta | 0.28 |
| Profit Margins | 35.00% |
| Website | https://www.vrtx.com |
As of Oct. 10, 2026, 8:09 a.m. EDT: Speculators are positioning for continued upside with significant out-of-the-money call open interest walls at 570 to 700 strikes for late 2026 and 2027, suggesting a bullish thesis on long-term growth. Conversely, put buyers are establishing a defensive floor around the 500 strike, while lower-strike puts show volume spikes in December and January, indicating hedging against a deeper correction. Implied volatility remains elevated across the board.
| Attribute | Value |
|---|---|
| 52 Week Change | 0.22992575 |
| Address1 | 50 Northern Avenue |
| All Time High | 560.25 |
| All Time Low | 3.25 |
| Ask | 506.35 |
| Ask Size | 1 |
| Audit Risk | 5 |
| Average Analyst Rating | 1.6 - Buy |
| Average Daily Volume10 Day | 1,038,680 |
| Average Daily Volume3 Month | 1,146,328 |
| Average Volume | 1,146,328 |
| Average Volume10Days | 1,038,680 |
| Beta | 0.281 |
| Bid | 512.17 |
| Bid Size | 2 |
| Board Risk | 5 |
| Book Value | 79.921 |
| City | Boston |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 6 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 507.0 |
| Current Ratio | 3.185 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,790,726,400 |
| Day High | 514.8 |
| Day Low | 506.0 |
| Debt To Equity | 9.767 |
| Display Name | Vertex Pharmaceuticals |
| Dividend Yield | 0.0 |
| Earnings Call Timestamp End | 1,793,649,600 |
| Earnings Call Timestamp Start | 1,793,649,600 |
| Earnings Growth | 0.08 |
| Earnings Quarterly Growth | 0.065 |
| Earnings Timestamp | 1,793,649,600 |
| Earnings Timestamp End | 1,793,649,600 |
| Earnings Timestamp Start | 1,793,649,600 |
| Ebitda | 5,100,499,968 |
| Ebitda Margins | 0.40521 |
| Enterprise To Ebitda | 24.043 |
| Enterprise To Revenue | 9.742 |
| Enterprise Value | 122,629,890,048 |
| Eps Current Year | 17.62606 |
| Eps Forward | 20.10614 |
| Eps Trailing Twelve Months | 17.17 |
| Esg Populated | 0 |
| Exchange | NMS |
| Exchange Data Delayed By | 15 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 521.062 |
| Fifty Day Average Change | -14.062012 |
| Fifty Day Average Change Percent | -0.026987214 |
| Fifty Two Week Change Percent | 22.992575 |
| Fifty Two Week High | 560.25 |
| Fifty Two Week High Change | -53.25 |
| Fifty Two Week High Change Percent | -0.095046856 |
| Fifty Two Week Low | 403.16 |
| Fifty Two Week Low Change | 103.84 |
| Fifty Two Week Low Change Percent | 0.25756523 |
| Fifty Two Week Range | 403.16 - 560.25 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 680,362,200,000 |
| Float Shares | 252,682,799 |
| Forward Eps | 20.10614 |
| Forward P E | 25.216177 |
| Free Cashflow | 2,627,887,616 |
| Full Exchange Name | NasdaqGS |
| Full Time Employees | 6,400 |
| Fullday Change | 1.2200012 |
| Fullday Change Percent | 0.2406314 |
| Fullday Price | 508.22 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,790,812,800 |
| Gross Margins | 0.54957 |
| Gross Profits | 6,917,600,256 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.00212 |
| Held Percent Institutions | 0.98002 |
| Implied Shares Outstanding | 253,300,000 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Ir Website | http://www.vrtx.com/finances.html |
| Is Earnings Date Estimate | 0 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 967,075,200 |
| Last Split Factor | 2:1 |
| Long Business Summary | Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The company also develops CASGEVY for the treatment of SCD and TDT; JOURNAVX for the treatment of acute pain in adults; VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1/2 clinical trial; inaxaplin for the treatment of APOL1-mediated kidney disease, which is in single Phase 2 trial; VX-264 for treating Type 1 Diabetes; VX-670 for the treatment of myotonic dystrophy type 1; and VX-407, a small molecule corrector for the treatment of autosomal dominant polycystic kidney disease. In addition, the company also operates as a clinical-stage pharmaceutical company, that focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company sells its products primarily to specialty pharmacy and distributors, wholesalers, retail pharmacies, hospitals, and clinics. Vertex Pharmaceuticals Incorporated has a strategic collaboration with AbCellera Biologics Inc. to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts. |
| Long Name | Vertex Pharmaceuticals Incorporated |
| Market | us_market |
| Market Cap | 128,423,100,416 |
| Market State | PRE |
| Max Age | 86,400 |
| Message Board Id | finmb_36235 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | 4,405,199,872 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 130,872,013,498 |
| Number Of Analyst Opinions | 28 |
| Open | 512.44 |
| Operating Cashflow | 4,292,900,096 |
| Operating Margins | 0.38055 |
| Overall Risk | 6 |
| Payout Ratio | 0.0 |
| Peg Ratio | 1.99 |
| Phone | 617 341 6100 |
| Pre Market Change | 1.2200012 |
| Pre Market Change Percent | 0.2406314 |
| Pre Market Price | 508.22 |
| Pre Market Time | 1,791,891,039 |
| Previous Close | 510.08 |
| Price Eps Current Year | 28.764227 |
| Price Hint | 2 |
| Price To Book | 6.343765 |
| Price To Sales Trailing12 Months | 10.202674 |
| Profit Margins | 0.34997 |
| Quick Ratio | 2.536 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | buy |
| Recommendation Mean | 1.625 |
| Region | US |
| Regular Market Change | -3.07999 |
| Regular Market Change Percent | -0.603824 |
| Regular Market Day High | 514.8 |
| Regular Market Day Low | 506.0 |
| Regular Market Day Range | 506.0 - 514.8 |
| Regular Market Open | 512.44 |
| Regular Market Previous Close | 510.08 |
| Regular Market Price | 507.0 |
| Regular Market Time | 1,791,835,201 |
| Regular Market Volume | 939,963 |
| Return On Assets | 0.11926 |
| Return On Equity | 0.23542999 |
| Revenue Growth | 0.125 |
| Revenue Per Share | 49.507 |
| Sand P52 Week Change | 0.17502642 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 6 |
| Shares Outstanding | 253,300,000 |
| Shares Percent Shares Out | 0.0178 |
| Shares Short | 4,503,200 |
| Shares Short Previous Month Date | 1,788,134,400 |
| Shares Short Prior Month | 4,659,749 |
| Short Name | Vertex Pharmaceuticals Incorpor |
| Short Percent Of Float | 0.0201 |
| Short Ratio | 4.39 |
| Source Interval | 15 |
| State | MA |
| Symbol | VRTX |
| Target High Price | 667.0 |
| Target Low Price | 350.0 |
| Target Mean Price | 571.4286 |
| Target Median Price | 578.0 |
| Total Cash | 7,852,400,128 |
| Total Cash Per Share | 30.981 |
| Total Debt | 1,977,600,000 |
| Total Revenue | 12,587,200,512 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | 17.17 |
| Trailing P E | 29.528246 |
| Trailing Peg Ratio | 1.8976 |
| Triggerable | 1 |
| Two Hundred Day Average | 475.13916 |
| Two Hundred Day Average Change | 31.86084 |
| Two Hundred Day Average Change Percent | 0.06705581 |
| Type Disp | Equity |
| Volume | 939,963 |
| Website | https://www.vrtx.com |
| Zip | 2,210 |